Nature Reviews Drug Discovery · Feb 2011
Tesamorelin
By Grunfeld C, Dritselis A, Kirkpatrick P
In November 2010, tesamorelin (Egrifta; Theratechnologies/EMD Serono), a growth hormone-releasing factor analogue, was approved by the US Food and Drug Administration for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.